“Bio-Betters” Could Be Good Business, But It’s Not For Genzyme – Termeer
This article was originally published in The Pink Sheet Daily
CEO Henri Termeer addresses how biotech companies are responding to news that Big Pharma wants to establish a position in follow-on biologics, at Goldman Sachs conference
You may also be interested in...
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.